

Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.
You can purchase shares of Arcturus Therapeutics (NASDAQ:ARCT) through any online brokerage.
Other companies in Arcturus Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Arcturus Therapeutics has a consensus price target of $31.08.
The stock price for Arcturus Therapeutics (NASDAQ: ARCT) is $10.65 last updated October 23, 2026 at 4:46 AM EDT.
There are no upcoming dividends for Arcturus Therapeutics.
Arcturus Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Arcturus Therapeutics.
Arcturus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities...